Accepted for/Published in: JMIR Public Health and Surveillance
Date Submitted: Apr 20, 2022
Date Accepted: Oct 18, 2022
Date Submitted to PubMed: Oct 20, 2022
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Risk of hospitalization and mortality after breakthrough SARS-CoV-2 infection by vaccine type utilizing medical claims data
ABSTRACT
Understanding the severity of SARS-CoV-2 breakthrough infections by vaccine type is important for making policy decisions regarding booster vaccinations. We compare the risks of hospitalization (n=1140) and mortality (n=159) in a SARS-CoV-2 positive cohort of 19,815 patients who were all fully vaccinated with either the Pfizer, Moderna or Janssen vaccines. Cox regression analysis comparing the three vaccines’ effectiveness in severity of the breakthrough infection showed lower hazard ratios for those receiving the Moderna vaccine and Pfizer vaccine (the lowest hazard rates being for Moderna), as compared to those who received the Janssen vaccine. Further, individuals who had a SARS-CoV-2 infection prior to vaccination had some increased protection over and above the protection already provided by the vaccines, from the risk of hospitalization (P<0.001) and mortality (P<0.05), independent of age, sex, comorbidities, and vaccine type.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.